Opioid use disorder — ED-initiated treatment and harm reduction
OUD treatment · Psychiatry / Behavioural
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
The ED is an opportunity to initiate opioid agonist treatment, provide take-home naloxone and link patients to community services, reducing overdose mortality. Buprenorphine induction (once in objective withdrawal) and harm-reduction measures are increasingly ED-led, coordinated with local substance-misuse services.
Red flags
- Respiratory depression or reduced GCS (overdose)
- Signs of injecting-related sepsis (endocarditis, abscess, DVT)
- Precipitated withdrawal after premature buprenorphine
- Concurrent benzodiazepine/alcohol use (additive respiratory depression)
- Pregnancy (specialist management needed)
Assessment
Differential diagnosis
- Opioid withdrawal (dysphoria, yawning, lacrimation, GI symptoms, dilated pupils)
- Opioid intoxication/overdose (pinpoint pupils, respiratory depression)
- Other drug withdrawal (alcohol, benzodiazepine)
- Sepsis or injection-related infection
- Coexisting mental illness
Investigations
- Objective withdrawal score (COWS) before buprenorphine induction
- Observations, capillary glucose
- Bloods: FBC, U&E, LFTs, CRP; blood-borne virus screen (offer BBV testing)
- ECG if methadone considered (QT) or polydrug use
- Assess injection sites for infection (DVT, abscess, endocarditis)
Management
- Confirm opioid use disorder and current state (withdrawal vs intoxication)
- For overdose, resuscitate and give naloxone titrated to restore breathing
- Offer opioid agonist treatment: induce buprenorphine only once in objective withdrawal (COWS >12) to avoid precipitated withdrawal
- Coordinate dosing with the patient's community prescriber/key worker (avoid double-dosing with methadone)
- Provide take-home naloxone and overdose-prevention education
- Offer blood-borne virus testing and vaccination, and treat injection-related complications
- Refer to community drug and alcohol services with warm handover
- Screen for and address mental-health comorbidity
Drugs & doses
Naloxone — 400 mcg IV/IM titrated (lower, e.g. 100 mcg, to avoid acute withdrawal) for overdose; take-home naloxone kit on discharge
Buprenorphine — 4 mg SL initial dose once COWS >12, repeat to 8-16 mg total on day 1 (induction)
Methadone — only continue/prescribe after confirming existing dose with the community prescriber (risk of toxicity)
Lofexidine — 0.8 mg PO for autonomic withdrawal symptoms as an adjunct
Metoclopramide/loperamide — symptomatic relief of nausea/diarrhoea in withdrawal
Disposition
Discharge stabilised patients with take-home naloxone and a warm referral to community drug services, after buprenorphine induction where appropriate; admit for injection-related sepsis or overdose complications, and involve liaison psychiatry for comorbidity.
Complications & pitfalls
- Overdose death
- Precipitated withdrawal from early buprenorphine
- Injection-related infections (endocarditis, abscess, blood-borne viruses)
- Methadone toxicity/QT prolongation
- Disengagement from services
Exam pearls
- Never induce buprenorphine until the patient is in objective withdrawal (COWS >12) — otherwise you precipitate withdrawal
- Always confirm an existing methadone dose with the prescriber before giving any — unconfirmed dosing can be fatal
- Take-home naloxone saves lives — supply it and teach its use
- The ED visit is a key engagement point; warm handover improves uptake
- Offer blood-borne virus testing and treat injection-site complications
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.